DrGraeme Sullivan
Lecturer
School of Pharmacy and Biomolecular Sciences
Orcid identifier0000-0001-5132-9349 (opens in a new tab)
- LecturerSchool of Pharmacy and Biomolecular Sciences
- Royal College of Surgeons in Ireland, Pharmacy and Biomolecular Sciences, 111 St Stephens Green - Ardilaun House, 1st Floor (Block B), Dublin, Ireland
BIOGRAPHY
Graeme Sullivan is a Lecturer at the School of Pharmacy and Biomolecular Sciences, RCSI. He undertook his undergraduate training in Trinity College Dublin, Ireland where he received an Edmund Burke Entrance Exhibition Award upon entry. He graduated from Dental School with B.A. B.Dent.Sc. (Hons) degrees from Trinity College Dublin, Ireland. Additionally, he received a P.G. Diploma (Dent. Ed.) from the University of Bristol, United Kingdom upon graduation with 1st class honours (with distinction) in 2017. He undertook his Ph.D. studies in Molecular Biology in the laboratory of Professor Séamus Martin at The Smurfit Institute of Genetics, Trinity College Dublin. During his doctoral studies his work explored innate immune signalling and inflammatory outcomes of proteolytic processing in an important group of cytokines, the interleukin-1 (IL-1) family. Their group was the first to discover the endogenous enzymatic activators of one of these subfamilies, IL-36 family cytokines.
Their research showed in biochemical, in vitro and in vivo experiments how these important cytokines drive inflammation in skin inflammatory diseases such as psoriasis. This discovery allowed them to design a patented panel of novel peptide-based mimetics that acted as pseudosubstrates for these enzymes with significant therapeutic potential. Utilising another approach they performed in silico screening and generated small molecule inhibitors that also showed utility in abrogating inflammation in psoriatic patient sample eluates. During his Ph.D., Sullivan and co-workers also deciphered an important role for ‘death receptors’ as immune-regulatory sentinels that, alongside their known role in apoptosis, also serve as endogenous cellular stress-associated molecular patterns (SAMPs) that can promote ER-stress associated inflammation, including that observed in response to conventional chemotherapies. In 2018, he successfully defended his thesis “Inflammatory outcomes of diverse forms of homeostatic perturbation” and was awarded Ph.D. from Trinity College Dublin in the same year. During his postdoctoral studies in the laboratory of Professor Martin, Dr. Sullivan and colleagues pursued research into a recently discovered and understudied member of the IL-1 family: IL-37. Contrary to the pre-eminent view in the field that IL-37 cytokine is anti-inflammatory and immune-suppressive, the group showed - for the first time - that activated IL-37 is, in fact, a pro-inflammatory cytokine. Additionally, they showed that IL-37 signals via the IL-36 receptor – another finding that was previously unknown. This work was recently published in Science Immunology (2022) and is within the top 5% of all research outputs measured by Altmetric.
Dr. Sullivan then joined the Targeted Therapeutics in Cancer (TTC) research group of Professor Tríona Ní Chonghaile at RCSI in 2021 and was awarded a prestigious Irish Cancer Society Translational Cancer Research Fellowship that year to explore his project “Defining the pro-survival signalling of the bone marrow microenvironment of multiple myeloma”. During his time in the TTC lab he published a review in Science Translational Medicine exploring the mechanisms of resistance that cancer cells use to overcome targeted cancer therapy with an important FDA-approved BCL2 antagonist, venetoclax (ABT-199). He also contributed to ongoing work in the TTC laboratory that uses PROTAC technology directed at putative drug targets important in cancer, including HDAC6. He is also actively engaged in Public Patient Involvement (PPI) in research through Multiple Myeloma Ireland and regularly presents his research at invited national and international meetings. He is also a current member of the Athena SWAN (data stream) committee. Dr Sullivan was recently promoted to Lecturer in the School of Pharmacy and Biomolecular Sciences, RCSI in 2023 where alongside his continued active research he employs the latest pedagogical techniques and teaches into the University’s Pharmacy, Medicine, Physician Associate and B.Sc.(advanced therapeutic technologies) programmes.
Their research showed in biochemical, in vitro and in vivo experiments how these important cytokines drive inflammation in skin inflammatory diseases such as psoriasis. This discovery allowed them to design a patented panel of novel peptide-based mimetics that acted as pseudosubstrates for these enzymes with significant therapeutic potential. Utilising another approach they performed in silico screening and generated small molecule inhibitors that also showed utility in abrogating inflammation in psoriatic patient sample eluates. During his Ph.D., Sullivan and co-workers also deciphered an important role for ‘death receptors’ as immune-regulatory sentinels that, alongside their known role in apoptosis, also serve as endogenous cellular stress-associated molecular patterns (SAMPs) that can promote ER-stress associated inflammation, including that observed in response to conventional chemotherapies. In 2018, he successfully defended his thesis “Inflammatory outcomes of diverse forms of homeostatic perturbation” and was awarded Ph.D. from Trinity College Dublin in the same year. During his postdoctoral studies in the laboratory of Professor Martin, Dr. Sullivan and colleagues pursued research into a recently discovered and understudied member of the IL-1 family: IL-37. Contrary to the pre-eminent view in the field that IL-37 cytokine is anti-inflammatory and immune-suppressive, the group showed - for the first time - that activated IL-37 is, in fact, a pro-inflammatory cytokine. Additionally, they showed that IL-37 signals via the IL-36 receptor – another finding that was previously unknown. This work was recently published in Science Immunology (2022) and is within the top 5% of all research outputs measured by Altmetric.
Dr. Sullivan then joined the Targeted Therapeutics in Cancer (TTC) research group of Professor Tríona Ní Chonghaile at RCSI in 2021 and was awarded a prestigious Irish Cancer Society Translational Cancer Research Fellowship that year to explore his project “Defining the pro-survival signalling of the bone marrow microenvironment of multiple myeloma”. During his time in the TTC lab he published a review in Science Translational Medicine exploring the mechanisms of resistance that cancer cells use to overcome targeted cancer therapy with an important FDA-approved BCL2 antagonist, venetoclax (ABT-199). He also contributed to ongoing work in the TTC laboratory that uses PROTAC technology directed at putative drug targets important in cancer, including HDAC6. He is also actively engaged in Public Patient Involvement (PPI) in research through Multiple Myeloma Ireland and regularly presents his research at invited national and international meetings. He is also a current member of the Athena SWAN (data stream) committee. Dr Sullivan was recently promoted to Lecturer in the School of Pharmacy and Biomolecular Sciences, RCSI in 2023 where alongside his continued active research he employs the latest pedagogical techniques and teaches into the University’s Pharmacy, Medicine, Physician Associate and B.Sc.(advanced therapeutic technologies) programmes.
ACADEMIC POSITIONS
- LecturerRoyal College of Surgeons in Ireland, Pharmacy and Biomolecular Sciences, Dublin, Ireland1 Sep 2023
- Postdoctoral Research Fellow (Irish Cancer Society Translational Cancer Research Fellow)Royal College of Surgeons in Ireland, Physiology and Medical Physics, Dublin, Ireland1 Oct 2021
- Postdoctoral Research Fellow (Targeted Therapeutics in Cancer Laboratory/Prof. Ní Chonghaile Lab)Royal College of Surgeons in Ireland, Physiology and Medical Physics, Dublin, Ireland1 Feb 2021 - 1 Oct 2021
- Postdoctoral Research Fellow (Molecular Cell Biology Laboratory/Prof. Martin Lab)Trinity College Dublin, Smurfit Institute of Genetics, Dublin, Ireland1 Nov 2018 - 1 Feb 2021
DEGREES
- Ph.D.Trinity College Dublin, Ireland2018
- BA BDentScTrinity College Dublin, Dublin, Ireland2006
CERTIFICATIONS
- P.G. Dip. (Dent. Ed.)University of Bristol, Bristol, United Kingdom2017
POSTGRADUATE TRAINING
- MFD (Part 1)Royal College of Surgeons in Ireland, Dublin, Ireland2010 - 2010
LANGUAGES
- EnglishCan read, write, speak, understand and peer review
- FrenchCan read, write, speak, understand and peer review
- IrishCan read, write, speak, understand and peer review
- PortugueseCan read, write, speak, understand and peer review
RESEARCH SUB-AREAS
- Cancer stem cells
- Drug resistance
- Drug development
- Technology Enhanced Learning
- Immunology
- Immunity
- Infection & Inflammation
- Molecular & physiological pharmaceutics
SUSTAINABLE DEVELOPMENT GOALS (UNSDGS)
- 3 Good Health and Well Being